Disclosed is the use of (-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxyylic acid methyl ester in free base or acid addition salt form in the manufacture of a pharmaceutical composition for the treatment, prevention, or delay of progression of a Parkinsons associated levodopa (L-dopa) induced dyskinesia.